Literature DB >> 21136628

Disease proteomics reveals altered basic gene expression regulation in leukocytes of Normal-Tension and Primary Open-Angle glaucoma patients.

Olga Golubnitschaja1, Kristina Yeghiazaryan, Kerstin Wunderlich, Hans H Schild, Josef Flammer.   

Abstract

Glaucomatous damage is a neurodegenerative eye disease and one of the leading causes of blindness with 67 million patients worldwide. Major currently challenging questions include early diagnosis, risk evaluation, and follow-up. Circulating leukocytes have been demonstrated as potentially important source of disease specific markers. The relevance of expression alterations in leukocytes for glaucomatous damage needs to be clarified. Noteworthy, gene expression patterns of trabecular meshwork and Schlemm's canal, which are anatomically and functionally highly relevant for glaucoma pathology, were shown to be similar to those of circulating leukocytes. Here, we report extensive alterations in characteristic protein expression patterns of circulating leukocytes for Normal-Tension and Primary Open-Angle Glaucoma, as revealed by analysis of 2-D PAGE images. Among most conservative alterations we found the protein spot identified by MALDI-TOF as basic transcription factor activating protein-2beta (AP-2β). Western-blot analysis demonstrated significantly increased protein expression rates of AP-2β in both Normal-Tension and Primary Open-Angle Glaucoma versus controls. AP proteins are essential factors of the basic transcription regulation; AP-2 proteins play a decisive role, particularly, in morphogenesis of eye. Conservative AP-2 up-regulation is of special importance in terms of basic transcriptional dysregulation that might be specific for glaucoma disease.
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2007        PMID: 21136628     DOI: 10.1002/prca.200700150

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  8 in total

1.  Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma.

Authors:  Michelle D Drewry; Pratap Challa; John G Kuchtey; Iris Navarro; Inas Helwa; Yanzhong Hu; Hongmei Mu; W Daniel Stamer; Rachel W Kuchtey; Yutao Liu
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

Review 2.  A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2013-02-05       Impact factor: 21.198

3.  Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Josef Flammer
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

4.  Advanced proteomics procedure as a detection tool for predictive screening in type 2 pre-Diabetes.

Authors:  Jadranka Koehn; Kurt Krapfenbauer
Journal:  EPMA J       Date:  2010-03-24       Impact factor: 6.543

5.  Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs.

Authors:  Kristina Yeghiazaryan; Josef Flammer; Olga Golubnitschaja
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

6.  Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients.

Authors:  M Mozaffarieh; A Schoetzau; M Sauter; M Grieshaber; S Orgül; O Golubnitschaja; J Flammer
Journal:  Mol Vis       Date:  2008-08-29       Impact factor: 2.367

7.  Predictive, Preventive and Personalised Medicine as the hardcore of 'Horizon 2020': EPMA position paper.

Authors:  Olga Golubnitschaja; Judita Kinkorova; Vincenzo Costigliola
Journal:  EPMA J       Date:  2014-04-07       Impact factor: 6.543

Review 8.  The discovery of the Flammer syndrome: a historical and personal perspective.

Authors:  Josef Flammer; Katarzyna Konieczka
Journal:  EPMA J       Date:  2017-05-22       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.